Literature DB >> 19473447

Reduction of syndecan-1 expression during lip carcinogenesis.

A Martínez1, M L Spencer, U Brethauer, P Grez, F J Marchesani, I G Rojas.   

Abstract

BACKGROUND: Actinic cheilitis (AC) is an oral pre-cancerous lesion that sometimes develops into lip squamous cell carcinoma (SCC). Syndecan-1, a transmembrane heparan sulfate proteoglycan, modulates cell-proliferation, adhesion, migration and angiogenesis. Malignant epithelial cells often down-regulate their own syndecan-1 production, and are capable of inducing aberrant syndecan-1 expression in stromal cells. The aim of this study was to evaluate the variations in syndecan-1 expression during lip carcinogenesis, in normal lip (NL), AC and well-differentiated lip SCC.
METHODS: Biopsies of NL vermillion (n = 19), AC (n = 23) and lip SCC (n = 24) were stained immunohistochemically for syndecan-1.
RESULTS: Syndecan-1 expression was significantly reduced in AC and lip SCC as compared to NL (P < 0.05), with a significant reduction in lip SCC as compared to AC (P < 0.0001). In lip SCC lesions, syndecan-1 expression at the epithelium overlying the tumor was increased when compared to the tumor itself (P < 0.03), but was significantly reduced as compared to AC and NL (P < 0.001).
CONCLUSION: The results showed that epithelial syndecan-1 expression is reduced as lip carcinogenesis progresses (NL>AC>lip SCC), suggesting that syndecan-1 could be a useful marker of malignant transformation in the lip.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473447     DOI: 10.1111/j.1600-0714.2009.00761.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  7 in total

1.  Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors.

Authors:  Anna Farnedi; Silvia Rossi; Nicoletta Bertani; Mariolina Gulli; Enrico Maria Silini; Maria Teresa Mucignat; Tito Poli; Enrico Sesenna; Davide Lanfranco; Lucio Montebugnoli; Elisa Leonardi; Claudio Marchetti; Renato Cocchi; Andrea Ambrosini-Spaltro; Maria Pia Foschini; Roberto Perris
Journal:  BMC Cancer       Date:  2015-05-03       Impact factor: 4.430

2.  Immunohistochemical analysis of syndecan-1 in leukoplakia and oral submucous fibrosis.

Authors:  Sushant S Kamat; G S Kumar; Ajit V Koshy
Journal:  Dent Res J (Isfahan)       Date:  2013-05

3.  Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases.

Authors:  Ivana Miše; Majda Vučić
Journal:  Anal Cell Pathol (Amst)       Date:  2018-07-29       Impact factor: 2.916

4.  Detection of Micro-invasion in Sudanese Oral Verrucous Carcinoma Samples Using Syndecan-1 Stain.

Authors:  Akb Elhassan; A M Suleiman; Nia El Dawi; Sofia B Mohamed
Journal:  Biomark Cancer       Date:  2019-09-16

5.  EBV-negative lymphoepithelial-like carcinoma of the lower lip.

Authors:  Luciana Yamamoto Almeida; Heitor Albergoni Silveira; Evânio Vilela Silva; Camila de Oliveira Barbeiro; Joaquim Augusto de Paula; Andreia Bufalino; Alfredo Ribeiro-Silva; Jorge Esquiche León
Journal:  Autops Case Rep       Date:  2019-12-13

6.  Novel processed form of syndecan-1 shed from SCC-9 cells plays a role in cell migration.

Authors:  Annelize Z B Aragão; Marília Belloni; Fernando M Simabuco; Mariana R Zanetti; Sami Yokoo; Romênia R Domingues; Rebeca Kawahara; Bianca A Pauletti; Anderson Gonçalves; Michelle Agostini; Edgard Graner; Ricardo D Coletta; Jay W Fox; Adriana F Paes Leme
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

7.  Actinic cheilitis: proposition and reproducibility of a clinical criterion.

Authors:  Nádia Antunes Poitevin; Mariana Sudati Rodrigues; Karen Loureiro Weigert; Carmen Lúcia Rodrigues Macedo; Rubem Beraldo Dos Santos
Journal:  BDJ Open       Date:  2017-08-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.